山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00719 山东新华制药股份

休市中 09-11 16:08:53

5.435

-0.105

-1.90%

最高5.515	最低5.420	成交量34.20万
今开5.515	昨收5.540	日振幅1.71%
总市值37.88亿	流通市值10.60亿	总股本6.97亿
成交额186.48万	换手率0.18%	流通股本1.95亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00719","market":"HK","secType":"STK","nameCN":"山东新华制药股份","latestPrice":5.435,"timestamp":1789114133848,"preClose":5.54,"halted":0,"volume":342000,"delay":0,"changeRate":-0.01895306859205784,"floatShares":195000000,"shares":697000000,"eps":0.49125423622442577,"marketStatus":"休市中","change":-0.105,"latestTime":"09-11 16:08:53","open":5.515,"high":5.515,"low":5.42,"amount":1864840,"amplitude":0.017148,"askPrice":5.5,"askSize":8000,"bidPrice":5.435,"bidSize":20000,"shortable":0,"etf":0,"ttmEps":0.36311524731705785,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":7,"adr":0,"listingDate":851961600000,"exchange":"SEHK","adjPreClose":5.54,"dividendRate":0.031815,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":1.3475177306557349,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"新华制药","latestPrice":12.81,"timestamp":1789110000000,"preClose":13.13,"halted":0,"volume":8135200,"delay":0,"premium":"-63.73"}},"requestUrl":"/m/hq/s/00719","defaultTab":"news","newsList":[{"id":"1185603184","title":"山东新华制药股份更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1185603184","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185603184?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:06","pubTimestamp":1788221180,"startTime":"0","endTime":"0","summary":"山东新华制药股份于2026年9月1日披露2026年8月股份变动月报表。报告期内，公司普通股包括在香港联交所上市的H股及未在香港联交所上市的A股，股本结构呈现总体稳定。数据显示，截至2026年8月31日，公司H股上月底与本月底均为195,000,000股，A股上月底与本月底均为501,683,435股。截至2026年8月31日，公司已确认满足香港联交所相关规则要求，并承诺严格遵守香港联交所《上市规则》及其他法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146339826","title":"山东新华制药：子公司阿奇霉素片通过一致性评价，瞄准年销6.7亿元市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1146339826","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146339826?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:38","pubTimestamp":1788165536,"startTime":"0","endTime":"0","summary":"2026年8月31日，山东新华制药股份有限公司公告称，其全资子公司山东淄博新达制药有限公司于2026年8月收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，阿奇霉素片已通过仿制药质量和疗效一致性评价。根据相关统计数据，2025年中国公立医疗机构阿奇霉素片销售额约为人民币6.7亿元。公司称，本次通过一致性评价有利于提升产品市场竞争力。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116866655","title":"山东新华制药股份有限公司（00719）获批盐酸达泊西汀片注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1116866655","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116866655?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:36","pubTimestamp":1787906215,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司8月28日公告称，公司已收到国家药品监督管理局核准签发的盐酸达泊西汀片《药品注册证书》。2025年4月，公司向国家药品监督管理局药品审评中心递交境内生产上市许可注册申报材料并获受理；2026年8月获批注册。公告援引数据显示，2025年中国公立医疗机构达泊西汀销售额约为人民币10.3亿元。公司表示，盐酸达泊西汀片的获批将进一步丰富其制剂产品系列并提升市场竞争力。公告日期：2026年8月28日。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101666638","title":"山东新华制药（00719）董事会审议通过2026年中期报告及衍生品交易等四项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1101666638","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101666638?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:03","pubTimestamp":1787648607,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司8月25日公告称，公司第十一届董事会第十二次会议已于2026年8月25日在山东省淄博市高新区鲁泰大道1号公司会议室召开。会议通知于2026年8月11日以电邮形式发出，应到会董事8名，实际参会8名，会议由董事长贺同庆主持，召集程序符合相关法律法规及公司章程规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180789483","title":"山东新华制药(00719)将发布衍生品交易管理制度 规范业务边界与风险控制","url":"https://stock-news.laohu8.com/highlight/detail?id=1180789483","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180789483?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:03","pubTimestamp":1787648604,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司8月25日在香港联交所公告称，公司将于2026年8月26日在巨潮资讯网披露《衍生品交易管理制度》全文，明确公司及其全资、控股子公司从事衍生品交易的范围、权限及风险控制措施。如预计动用的交易保证金和权利金上限占最近一期经审计净利润50%以上且绝对金额超过500万元人民币，或任一交易日最高合约价值占最近一期经审计净资产50%以上且绝对金额超过5,000万元人民币，须进一步提交股东大会审议；","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164732888","title":"山东新华制药股份（00719）调整会计政策：执行《企业会计准则解释第20号》，对财务无重大影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1164732888","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164732888?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:03","pubTimestamp":1787648597,"startTime":"0","endTime":"0","summary":"山东新华制药股份8月25日公告称，公司于同日召开第十一届董事会第十二次会议，通过《关于会计政策变更的议案》，决定自即日起执行财政部2026年6月4日发布的《企业会计准则解释第20号》。此次会计政策变更无需提交股东大会审议。公司表示，变更后的会计政策可更客观、公允地反映财务状况和经营成果，不会对现有财务状况、经营成果及现金流量产生重大影响，也不涉及前期财务数据调整。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197131255","title":"山东新华制药股份（00719）拟在12个月内开展不超过2亿元衍生品套期保值","url":"https://stock-news.laohu8.com/highlight/detail?id=1197131255","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197131255?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:03","pubTimestamp":1787648586,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司8月25日公告称，公司第十一届董事会第十二次会议审议通过《关于开展衍生品套期保值交易业务的议案》，同意自议案通过之日起12个月内开展衍生品套期保值交易业务。根据公告，授权有效期内任一时点未到期的衍生品合约名义本金合计不超过等值人民币2亿元，该额度可循环使用。单笔衍生品合约交割期限不超过12个月，全部资金来源于公司自有经营资金，不使用募集资金。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662876777","title":"山东新华制药股份(00719.HK)公布中期业绩 归母净利润约1.49亿元 同比减少33.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662876777","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662876777?lang=zh_cn&edition=full","pubTime":"2026-08-25 16:57","pubTimestamp":1787648243,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00719","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661473242","title":"医美板块整体承压 时代天使（06699）跌2.53%、四环医药（00460）跌2.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661473242","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661473242?lang=zh_cn&edition=full","pubTime":"2026-08-24 10:33","pubTimestamp":1787538824,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美板块整体承压，截至发稿，昊海生物科技 跌5.16%，时代天使跌2.53%，复星医药跌2.30%，四环医药跌2.29%，山东新华制药股份跌1.37%，现代牙科跌1.22%。华龙证券新近研究指，企业层面，国内医美企业持续突破海外监管认证，海外市场有望成为重要增长第二曲线，行业高质量发展态势明确。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989117","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1593","BK1583","00719","BK1191","BK1161","03600","BK1515","BK1600","06699","06826","02196","BK1587","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661133265","title":"山东新华制药股份(00719)：获得达格列净片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2661133265","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661133265?lang=zh_cn&edition=full","pubTime":"2026-08-21 16:46","pubTimestamp":1787301977,"startTime":"0","endTime":"0","summary":"智通财经APP讯，山东新华制药股份 发布公告，近日，公司收到国家药品监督管理局核准签发的达格列净片《药品注册证书》。2025年3月，新华制药向国家药品监督管理局药品审评中心递交达格列净片境内生产药品上市许可注册申报资料并获受理，2026年8月获得《药品注册证书》，审评结论为批准注册。根据相关统计数据，2025年中国公立医疗机构达格列净片销售额约为人民币114亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"山东新华制药股份(00719)：获得达格列净片药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","00719","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134436187","title":"山东新华制药股份（00719）获批达格列净片药品注册证书 丰富糖尿病及心衰治疗产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=1134436187","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134436187?lang=zh_cn&edition=full","pubTime":"2026-08-21 16:46","pubTimestamp":1787301974,"startTime":"0","endTime":"0","summary":"2026年8月21日，山东新华制药股份有限公司公告称，公司已于当日收到国家药品监督管理局核准签发的达格列净片《药品注册证书》，批准文号为“国药准字H20265648、国药准字H20265670”。该产品注册分类为化学药品4类，剂型为片剂，规格分别为10mg和5mg，药品属性为处方药。公司表示，本次获批将进一步丰富其产品线，提升市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194549112","title":"山东新华制药股份（00719）定于8月25日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1194549112","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194549112?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:51","pubTimestamp":1786438279,"startTime":"0","endTime":"0","summary":"山东新华制药股份（00719）8月11日公告称，公司董事会将于2026年8月25日（星期二）上午9时30分，在中国山东省淄博市高新区鲁泰大道1号公司会议室召开董事会会议。会议拟审议及批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩，并处理其他适用事宜。\n公告同时列明，公司董事会目前由三位执行董事、四位独立非执行董事及一位非执行董事组成，分别为：\n1. 执行董事：贺同庆（董事长）、徐文辉、侯宁  \n2. 独立非执行董事：潘广成、朱建伟、凌沛学、张菁菁  \n3. 非执行董事：张成勇\n本次会议有关决议结果将另行公布。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166508519","title":"山东新华制药7月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1166508519","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166508519?lang=zh_cn&edition=full","pubTime":"2026-08-03 08:05","pubTimestamp":1785715545,"startTime":"0","endTime":"0","summary":"山东新华制药股份于2026年8月3日披露2026年7月31日止的证券变动月报表。至7月底，公司法定/注册股本总额为人民币696,683,435元。其中，H股及A股数量与上月末相同，相关股本保持稳定，库存股份维持为零。根据公告，截至2026年7月31日，公司整体股本维持稳定，未有出现股份发行、回购或库存股份的增减变动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654500999","title":"易方达基金增持山东新华制药股份(00719)19.8万股 每股作价约6.26港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654500999","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654500999?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:10","pubTimestamp":1785237015,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月22日，易方达基金增持山东新华制药股份(00719)19.80万股，每股作价6.2566港元，总金额约为123.88万港元。增持后最新持股数目为1379.80万股，最新持股比例为7.08%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1191","00719","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181368171","title":"山东新华制药发布2025年度A股派息实施公告 每10股派现1.50元","url":"https://stock-news.laohu8.com/highlight/detail?id=1181368171","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181368171?lang=zh_cn&edition=full","pubTime":"2026-07-22 17:31","pubTimestamp":1784712678,"startTime":"0","endTime":"0","summary":"2026年7月23日，山东新华制药股份有限公司披露2025年度A股派息实施公告。根据公告，公司将按现有A股股本501,683,435股为基数，向A股股东每10股派发现金红利人民币1.50元（含税）。本次派息的A股股权登记日为2026年7月30日，除权除息日为2026年7月31日。如需咨询，投资者可联系山东新华制药股份有限公司董事会秘书办公室，电话0533-2196024。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652400126","title":"易方达基金管理有限公司增持山东新华制药股份(00719.HK)79万股 每股作价约6.06港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652400126","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652400126?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:11","pubTimestamp":1784286716,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1191","00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118519530","title":"港股直击 | 山东新华制药升近4%，携手科兴制药推动高纯度EPA制剂出海中东","url":"https://stock-news.laohu8.com/highlight/detail?id=1118519530","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118519530?lang=zh_cn&edition=full","pubTime":"2026-07-13 14:34","pubTimestamp":1783924475,"startTime":"0","endTime":"0","summary":" $山东新华制药股份(00719)$ 升超4%，截至发稿，升3.79%，报6.02港元，成交额999.02万港元。消息面上，据科兴制药官微消息，近日，科兴制药与山东新华制药股份有限公司(简称“新华制药”)再度携手，就二十碳五烯酸乙酯软胶囊出海沙特阿拉伯和阿联酋达成合作。这是双方继碳酸司维拉姆片之后的又一重要合作，共同推动国产高纯度EPA制剂进入中东两大核心医药市场。","market":"hk","thumbnail":"https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcSDi5NcYQXAF9EePsXpljCfbTqBrVjFM8as30dILDSajA&s=10","type":0,"news_type":0,"thumbnails":["https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcSDi5NcYQXAF9EePsXpljCfbTqBrVjFM8as30dILDSajA&s=10"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651319523","title":"港股异动 | 山东新华制药股份(00719)涨超4% 与科兴制药就二十碳五烯酸乙酯软胶囊出海中东达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651319523","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651319523?lang=zh_cn&edition=full","pubTime":"2026-07-13 14:23","pubTimestamp":1783923780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，山东新华制药股份(00719)涨超4%，截至发稿，涨3.79%，报6.02港元，成交额999.02万港元。消息面上，据科兴制药官微消息，近日，科兴制药与山东新华制药股份有限公司(简称“新华制药”)再度携手，就二十碳五烯酸乙酯软胶囊出海沙特阿拉伯和阿联酋达成合作。这是双方继碳酸司维拉姆片之后的又一重要合作，共同推动国产高纯度EPA制剂进入中东两大核心医药市场。新华制药二十碳五烯酸乙酯软胶囊于2025年6月获得国家药品监督管理局颁发的《药品注册证书》，实现国产EPA制剂从原料到制剂的全链条自主可控。目前，该药品已向美国食品药品监督管理局(FDA)递交注册申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK1191","BK0239","00719","688136","BK1515","BK4585","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650715150","title":"山东新华制药股份获易方达基金增持137.6万股 每股作价约6.09港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2650715150","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650715150?lang=zh_cn&edition=full","pubTime":"2026-07-12 15:17","pubTimestamp":1783840620,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新数据显示，7月6日，易方达基金管理有限公司增持山东新华制药股份（00719）137.6万股，每股作价6.0869港元，总金额约为837.56万港元。增持后最新持股数目为1026.6万股，最新持股比例为5.26%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-07-12/doc-inihppwh9802382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","BK1191","BK1515","00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650297182","title":"易方达基金增持山东新华制药股份(00719)137.6万股 每股作价约6.09港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2650297182","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650297182?lang=zh_cn&edition=full","pubTime":"2026-07-10 19:23","pubTimestamp":1783682617,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月6日，易方达基金管理有限公司增持山东新华制药股份(00719)137.6万股，每股作价6.0869港元，总金额约为837.56万港元。增持后最新持股数目为1026.6万股，最新持股比例为5.26%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1191","00719","EWH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xhzy.com","stockEarnings":[{"period":"1week","weight":-0.0381},{"period":"1month","weight":-0.0942},{"period":"3month","weight":-0.0214},{"period":"6month","weight":-0.1632},{"period":"1year","weight":-0.2547},{"period":"ytd","weight":-0.1505}],"compareEarnings":[{"period":"1week","weight":-0.033},{"period":"1month","weight":-0.0249},{"period":"3month","weight":0.0035},{"period":"6month","weight":-0.0259},{"period":"1year","weight":-0.0491},{"period":"ytd","weight":-0.0322}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"山东新华制药股份有限公司是一家主要从事化学原料药、制剂及化工产品的开发、制造和销售的中国公司。该公司运营三个分部。化学原料药分部主要从事咖啡因系列、布洛芬系列、阿司匹林系列、多巴系列、巴比妥系列及吡哌酸等解热镇痛类原料药的开发、制造及销售。制剂分部主要从事吡哌酸片、安痛定及尼莫地平片等片剂、针剂及胶囊剂等制剂的开发、制造及销售。医药中间体及其他产品分部主要从事医药中间体及其他产品的开发、制造及销售。该公司主要在中国国内市场及美洲和欧洲等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.012135},{"month":2,"riseRate":0.766667,"avgChangeRate":0.099902},{"month":3,"riseRate":0.433333,"avgChangeRate":-0.007748},{"month":4,"riseRate":0.7,"avgChangeRate":0.100629},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.000855},{"month":6,"riseRate":0.433333,"avgChangeRate":-0.005711},{"month":7,"riseRate":0.6,"avgChangeRate":0.01986},{"month":8,"riseRate":0.275862,"avgChangeRate":-0.043444},{"month":9,"riseRate":0.344828,"avgChangeRate":-0.018722},{"month":10,"riseRate":0.448276,"avgChangeRate":0.009018},{"month":11,"riseRate":0.551724,"avgChangeRate":0.012197},{"month":12,"riseRate":0.586207,"avgChangeRate":0.023647}],"exchange":"SEHK","name":"山东新华制药股份","nameEN":"SHANDONG XINHUA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供山东新华制药股份(00719)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"山东新华制药股份,00719,山东新华制药股份股票,山东新华制药股份股票老虎,山东新华制药股份股票老虎国际,山东新华制药股份行情,山东新华制药股份股票行情,山东新华制药股份股价,山东新华制药股份股市,山东新华制药股份股票价格,山东新华制药股份股票交易,山东新华制药股份股票购买,山东新华制药股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供山东新华制药股份(00719)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}